IDH1 and neoplasm: Preclinical data suggests that IDH1-R132H-specific polypeptide vaccines can induce specific therapeutic T helper cell responses and exhibit efficacy against IDH1-R132H-positive tumours in isogenic MHC human mice (145, 147–149).